HCPCS G0429: Dermal Filler Injection for Facial Lipodystrophy Syndrome
HCPCS Level II code G0429 represents dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS), a condition often seen in patients receiving highly active antiretroviral therapy. Nationally, this code identifies outpatient procedures intended to restore facial soft-tissue volume for functional and reconstructive purposes related to LDS. Use of G0429 matters for payers and providers because it distinguishes reconstructive filler treatment for a recognized syndrome from cosmetic-only interventions, influencing coverage considerations and claims adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise guide to what G0429 denotes clinically and operationally, plus an overview of payer coverage patterns and billing considerations. The publication outlines typical sites of service, common modifiers (listed separately), and areas where policy updates or clarifications commonly arise for injectable dermal filler services for LDS.
This summary equips billing, coding, and compliance teams with a clear understanding of the code’s clinical intent, the typical outpatient service setting, and the payer landscape to inform documentation, claim submission, and policy review. Data not available in the input is noted where applicable in detailed sections of the publication.
Customize your policy alerts
Sign up for hcpcs G0429 policy alerts
Get alerted when payer policies referencing G0429 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code G0429 describes dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS), for example when associated with highly active antiretroviral therapy. The service is a cosmetic/reconstructive soft-tissue augmentation using injectable dermal fillers to restore facial volume lost from lipodystrophy. The typical site of service is an outpatient or ambulatory care setting such as a dermatology clinic, plastic surgery clinic, or other outpatient procedural suite where minimally invasive aesthetic or reconstructive injections are performed.